top of page
Home Image 3.jpg

Project C.U.R.E. has been the largest provider of donated medical supplies and equipment in the world. Project C.U.R.E. has long been established in low and medium resource countries as the largest distributors of used and new medical equipment, including C.U.R.E. Kits and now Cure Cervical Cancer Kits. Additionally, Project C.U.R.E. is well supported by many internationally known partners and has been for over 30 years.

Project C.U.R.E. currently delivers used and new medical equipment as well as their C.U.R.E. Kits to 111 countries.

Project C.U.R.E.’s Cargo program delivers semi-trailer-sized cargo containers carrying medical donations to under-resourced hospitals, clinics and community health centres in developing countries. They manage a complex inspection, inventory and logistics process that annually places millions of dollars' worth of medical supplies and modern equipment directly into the hands of doctors and nurses, so they can provide quality care to their patients, many of whom are women and young children.


Cure Cervical Cancer, Inc. in partnership with Global Cancer Care and Research Institute intends to provide an answer to the problem of cervical cancer deaths and morbidity in low to middle resource countries where screening and treatment is non-existent or inadequate. We plan to do our first clinical trial in December, 2021 with the Cervical Cancer Cure Kits that contain: 1. A unique, novel speculum which overcomes the limitations of the existing speculum such that all interested personnel can be easily trained to screen and treat lesions of the uterine cervix. 2. A canister-based cryogen that eliminates the bulky, expensive, electricity-dependent cryosurgical units. 3. A hand-held colposcope for better visualization of the cervix.

The kit further includes acetic acid employing a method known as visual inspection with acetic acid (VIA). This is a point-of-care (POC) kit that can be combined with standard screening for HIV with possible applications for self-screening in the future (self-PAPs). VIA is highly sensitive (89%), highly specific (87%) and accurate (87%) vs. PAP (93%).

bottom of page